Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
暂无分享,去创建一个
F. Bertucci | J. Lemonnier | J. Bonneterre | H. Bonnefoi | T. Petit | G. Romieu | F. Bidard | J. Pierga | P. Viens | M. Mouret-Reynier | P. Soulié | F. Dalenc | P. Barthélémy | T. Bachelot | E. Charafe-Jauffret | P. Kerbrat | J. Ferrero | F. Lerebours | A. Autret | A. Lortholary | A. Hardy-Bessard | C. Lévy | J. Eymard | M. Fekih | M. Deblock
[1] C. Caldas,et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[2] C. Nicolazzo,et al. Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[3] J. Lemonnier,et al. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] S. Paik,et al. Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 , 2015 .
[5] E. Perez,et al. Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) , 2015 .
[6] M. Cristofanilli,et al. IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model. , 2015, Journal of the National Cancer Institute. Monographs.
[7] J. Weeks,et al. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. , 2015, Clinical breast cancer.
[8] D. Berry,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Bonneterre,et al. Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data , 2014, Clinical Cancer Research.
[10] M. Rezai,et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] S. Seshan,et al. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. , 2014, Human pathology.
[12] D. Nielsen,et al. A systematic review of bevacizumab efficacy in breast cancer. , 2014, Cancer treatment reviews.
[13] W. Gradishar,et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. , 2014 .
[14] G. Hortobagyi,et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Buyse,et al. Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer , 2013 .
[16] M. Parmar,et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.
[17] J. Hecht,et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.
[18] T. Delozier,et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. , 2012, The Lancet. Oncology.
[19] Tanja Fehm,et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.
[20] James A Young,et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.
[21] M. Wicha,et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.
[22] Tanja Fehm,et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells , 2012, Breast Cancer Research.
[23] Jacobus Pfisterer,et al. A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.
[24] L. Frati,et al. Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] S. Merajver,et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] T. Fehm,et al. Abstract PD04-06: Changes in Circulating Tumor and Endothelial Cells in Peripheral Blood of Patients Treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study “GeparQuinto” , 2010 .
[27] X. Pivot,et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] E. van Marck,et al. Is there a role for mammary stem cells in inflammatory breast carcinoma? , 2010, Cancer.
[29] T. Fehm,et al. Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.
[30] J. Baselga,et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.
[31] H. Tesch,et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. Bertucci,et al. Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.
[33] Seigo Nakamura,et al. Molecular targets for treatment of inflammatory breast cancer , 2009, Nature Reviews Clinical Oncology.
[34] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[35] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[36] Anne Vincent-Salomon,et al. Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.
[37] Yi Xiao,et al. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. , 2008, The American journal of pathology.
[38] T. Kroll,et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] F. Bertucci,et al. Defining the molecular biology of inflammatory breast cancer. , 2008, Seminars in oncology.
[40] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[41] M. Untch,et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] Kevin Camphausen,et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Y. Yen,et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. , 2004, Journal of Clinical Oncology.
[44] F. Bertucci,et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment , 2004, Bone Marrow Transplantation.
[45] G. Hortobagyi,et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma , 2001, Cancer.
[46] T. Delozier,et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial) , 1999, British Journal of Cancer.
[47] R. Vij,et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] E. Shpall,et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Z. Baloch,et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.
[50] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.